USE OF FENOLDOPAM IN POSTCARDIOTOMY LOW OUTPUT SYNDROME

非诺多泮在心脏切开术后低输出量综合征中的应用

• 批准号: 3942870
• 负责人: R E CLARK
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3942870
• 关键词: heart circulation; heart output disorder; heart surgery; hemodynamics; human subject; human therapy evaluation; kidney circulation; kidney disorder chemotherapy; renal failure; vasodilatation; vasodilators

The effect of the selective dopamine receptor agonist fenoldopam on renal perfusion, renal function and cardiac function and cardiac hemodynamics will be assessed in 30 patients who demonstrate low cardiac output syndrome (LCOS). Ten patients without low cardiac output syndrome following open heart operation will serve as controls. Fenoldopam is an investigational agent that is 6x as potent as dopamine in causing renal vasodilation. It should be an ideal agent in reversing the renal hypoperfusion thought to play a significant role in acute renal failure following post-cardiotomy low output syndrome. Fenoldopam also causes systemic vasodilatation and should provide effective afterload reduction.

选择性多巴胺受体激动剂非诺多泮 对肾灌注、肾功能和心脏功能的影响， 将在30名患者中评估心脏血流动力学， 低心排血量综合征（LCOS） 十个病人 心内直视术后无低心排综合征 操作将作为对照。 非诺多泮是一种研究性药物，其效力是 多巴胺引起肾血管舒张。 它应该是一种理想 逆转肾灌注不足的药物被认为是一种 在心脏切开术后急性肾功能衰竭中重要作用 低输出综合征 非诺多泮还引起全身性 血管扩张，并应提供有效的后负荷减少。